AlphaRose Therapeutics — Posts

A quick update:

It's been nonstop at AlphaRose! We just came back from JPM with some significant investor conversations, and heading to Saudi Arabia at the end of Jan for more. Our valuation is rising, and our team is growing! We have a $3M CLN open that should close soon, with $2.1M already filled. We're open to investors that want to make an impact in patients lives with genetic medicine, changing the way that we think about how we make and deploy the medicine of the future for patients.

• We acquired RareLabs, a personalized genetic medicine lab here in Austin, Tx with an achievable goal of $1.2M in revenue in 2026. We've created 8 new treatments in the lab, which two patients are already on and seeing results.
• We're in multiple conversations with institutions for AlphaRose to acquire clinical stage assets for our Rare HoldCo model. (these most likely will yield a 200-600% return at peak AR, currently only available to our company investors)

Lastly, we're very excited about the MHRA and FDA guidances, that are doing what we've been preparing all along - approving the process of making medicines at scale. Check out this latest article from the economist, hot of the press: https://www.economist.com/science-and-technology/2026/01/19/treatment-of-a-teenager-with-an-ultra-rare-condition-is-a-medical-milestone

If you're interested in the future of medicine. Now is the time. The Note is almost filled, the minimum investment currently is $50k, and comes with warrants. After this note closes in Feb 2026, we enter our Series Seed Round with a significantly higher valuation, and terms. Reach out about the opportunity if it seems like a potential fit.

Patients are waiting,

Casey McPherson & AlphaRose Team

AlphaRose has built significant value over this last quarter, with 5B+ in potential revenue waiting to be unlocked. Our team is very excited about the incredible opportunities in front of us.

To that end, we are announcing a $2m Convertible Note that just opened, Oct 1st - Nov 30th for select investors. The note is filling fast. Please reach out to me immediately if you have interest. (casey@alpharose.com / 512.940.4164)

Some significant markers:

• We are currently now advancing 5 genetic treatments in the pipeline. ($XB in potential annual revenue)
• We are continuing to develop our two proprietary RNA technologies (abcDNA and SOT Caller) poised for large licensing deals as early as 2026. (see Merck and Skyhawk as an example)
• We are in multiple discussions with potential partners in biotech, venture, and healthcare systems.
• We closed our Reg CF Round Sept 30th with $1.6M in additional investment.
• We have two non-dilutive grants we're working on totaling over $50M in potential capital.
• We have board approval to acquire RareLabs, a private genetic treatment lab in Austin, Tx, bringing in $1M in AR.

AlphaRose is poised to be a revenue generating company in 2026 and beyond, and we are excited about the impact we will be making for patients with genetic diseases for generations to come!

For more info on the note and a company update Click here: https://alpharose.info/introdeckcln2

Sincerely,

Casey McPherson and the AlphaRose Team

Check out the latest article in NewsWeek featuring our founder's story. We have the technology to treat and even cure many of these diseases. The industry lacks the business models and systems to do it at scale and speed. AlphaRose aims to fix this problem. Patients are waiting!

https://www.newsweek.com/research-moves-slowly-rare-diseases-dontso-patients-arent-waiting-2090277